Slowed gastric emptying Helping prolong the feeling of fullness
GLP-1 has demonstrated notable immunomodulatory properties by promoting glycolysis over oxidative phosphorylation, thereby reducing the levels of inflammatory mediators, oxidative stress, and organ dysfunction
Increase water consumption
Despite the fact that they're often referred to as "natural" alternatives to GLP-1 agonist medications, Metzgar says it's important to differentiate between the two
Based on the typical UK regulatory pathway, the most realistic timeline is: Late 2026 / early 2027: Eli Lilly expected to submit regulatory filings to the FDA and MHRA following completion of the remaining TRIUMPH Phase 3 readouts Late 2027 to mid-2028: Possible MHRA marketing authorisation, allowing private UK prescribing 2028 to 2029 onwards: Possible NHS availability following a NICE technology appraisal and NHS commissioning decisions Timelines may differ across the four UK nations, as Scotland, Wales, and Northern Ireland assess medicines separately through the Scottish Medicines Consortium (SMC), All Wales Medicines Strategy Group (AWMSG), and the Department of Health Northern Ireland respectively
The recommended foods while on semaglutide and foods to avoid on tirzepatide provide specific dietary guidance
